Comparative Pharmacology
Head-to-head clinical analysis: DEAPRIL ST versus ENALAPRILAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEAPRIL ST versus ENALAPRILAT.
DEAPRIL-ST vs ENALAPRILAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor. Inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and cardiac workload.
Oral: 2.5 mg twice daily, titrated up to 5 mg twice daily as tolerated. Maximum dose: 10 mg daily.
1.25 mg IV over 5 minutes every 6 hours; may increase to 5 mg IV every 6 hours if needed.
None Documented
None Documented
Clinical Note
moderateEnalaprilat + Benzydamine
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Benzydamine."
Clinical Note
moderateEnalaprilat + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Enalaprilat."
Clinical Note
moderateEnalaprilat + Droxicam
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Droxicam."
Clinical Note
moderateEnalaprilat + Loxoprofen
8-10 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal half-life: 35 hours (prolonged in renal impairment; accumulates with CrCl <30 mL/min)
Renal (90% as unchanged drug), biliary/fecal (10%)
Renal: 60-80% unchanged; biliary/fecal: minimal (<10%)
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Loxoprofen."